A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium

Current Medical Research and Opinion

Volumn 24, Issue 3, 2008, Pages 737-751

  Martin, Monique ^a,d   Moore, Lee ^a   Quilici, Sibilia ^a   Decramer, Marc ^b   Simoens, Steven ^c  

^a i3 Innovus   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Beaufort House ^*  (United Kingdom)

Author keywords

Antimicrobial resistance; Community acquired pneumonia; Cost effectiveness analysis; Decision analytic model; Moxifloxacin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEFUROXIME; CLARITHROMYCIN; MOXIFLOXACIN;

ANTIMICROBIAL THERAPY; ARTICLE; BELGIUM; COMMUNITY ACQUIRED PNEUMONIA; DEATH; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SENSITIVITY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; TREATMENT FAILURE; TREATMENT OUTCOME;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BELGIUM; CEFUROXIME; CLARITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; PNEUMONIA, BACTERIAL; QUINOLINES;

EID: 41149114135     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X273336     Document Type: Article

References (45)

1. Almirall J, Bolibar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000;15:757-63
2. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993;137:977-88 3. Anderson RN. Deaths: leading causes for 2000. Natl Vital Stat Rep 2002;50:1-86
3. Talwar A, Lee H, Fein A. Community-acquired pneumonia: what is relevant and what is not? Curr Opin Pulm Med 2007;13:177-85
4. Grossman RF, Rotschafer JC, Tan JS. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med 2005; 118(Suppl 7A);29-38
5. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820-37
6. Lave JR, Lin CJ, Fine MJ, et al. The cost of treating patients with community-acquired pneumonia. Semin Respir Crit Care Med 1999;20:189-97
7. Fine MJ, Pratt HM, Obrosky DS, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 2000;109:378-85
8. Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med 1999;159:970-80
9. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Engl J Med 1997;336:243-50
10. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82
11. Aliyu ZY, Aliyu MH, McCormick K. Determinants for hospitalization in 'low-risk' community acquired pneumonia. BMC Infect Dis 2003;3:11
12. Carratala J, Martin-Herrero JE, Mykietiuk A, et al. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones. Clin Microbiol Infect 2006;12:2-11
13. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-80
14. Simoens S, Verhaegen J, Laekeman G, Peetermans WE. Treating respiratory tract infections in ambulatory care in Belgium: fluoroquinolone consumption and resistance development. Int J Antimicrob Agents 2005;26:62-8
15. Institut Pasteur. Evolution of fluoroquinolone resistance and detection of resistance mechanisms in clinical isolates of Streptococcus pneumoniae collected in Belgium in 1995-2005. Institut Pasteur. Brussels, 2006. Available at www.pasteur.be/pasteur_fr/index5930.html?page=antibiotic_research [last accessed 4 January 2008]
16. File Jr TM. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med 2004;117(Suppl 3A);39-50
17. Belgian Antibiotic Policy Coordination Committee. Belgian guide for anti-infectious treatment in ambulatory practice. Brussels: Belgian Antibiotic Policy Coordination Committee; 2006
18. Martin M, Quilici S, File T, et al. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. J Antimicrob Chemother 2007;59:977-89
19. Valcke Y. CAP guidelines: why differences between Belgian and American/Canadian guidelines? Louvain: Université Catholique de Louvain; 2001. Available at: http://www.farm.ucl.ac.be/seminfec//Atelier-Mandell-23-11- 01/Valcke/Valcke.pdf [last accessed 4 January 2008]
20. Jones ME, Blosser-Middleton RS, Critchley IA, et al. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001. Clin Microbiol Infect 2003;9:590-9
21. Welte T, Marre R, Suttorp N. What is new in the treatment of community-acquired pneumonia? Med Klin (Munich) 2006;101:313-20
22. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults [Infectious Diseases Society of America]. Clin Infect Dis 2000;31:347-82 24. Laurichesse H, Gerbaud L, Baud O, et al. Hospitalization decision for ambulatory patients with community-acquired pneumonia: a prospective study with general practitioners in France. Infection 2001;29:320-5
23. Torres A, Muir JF, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003;21:135-43
24. Petitpretz P, Arvis P, Marel M, et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119:185-95
25. Hoeffken G, Meyer HP, Winter J, Verhoef L. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001;95:553-64
26. Faich GA, Morganroth J, Whitehouse AB, et al. Clinical experience with moxifloxacin in patients with respiratory tract infections. Ann Pharmacother 2004;38:749-54
27. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004;98:708-20
28. Higuera F, Hidalgo H, Feris J, et al. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996;37:555-64
29. Mathers DL, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004;26:48-62
30. Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004;54:515-23
31. Gordon KA, Biedenbach DJ, Jones RN. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003;46:285-9
32. Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229-46
33. Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis 2003;7(Suppl 1):S13-S20 36. Dagan R. Achieving bacterial eradication using pharmacokinetic/ pharmacodynamic principles. Int J Infect Dis 2003;7(Suppl 1):S21-S26
34. Hoban D, Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother 2002;50(Suppl S1):49-59
35. Institut Pasteur. Presence of macrolide resistance mechanisms in clinical isolates of Streptococcus pneumoniae collected in Belgium in 1995-2005. Institut PasteurP: Brussels; 2006. Available at www.pasteur.be/pasteur_fr/ index5930.html?page=antibiotic_research [last accessed 30 January 2007]
36. Reinert RR, Simic S, AlLahham A, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: results of a national surveillance study. J Clin Microbiol 2001;39:1187-9
37. Institut National d'Assurance Maladie-Invalidité (INAMI). Brussels, 2006. Available at: www.inami.fgov.be [last accessed 30 January 2007]
38. Fantin B, Aubert JP, Unger P, et al. Clinical evaluation of the management of community-acquired pneumonia by general practitioners in France. Chest 2001;120:185-92
39. Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community-acquired pneumonia in an employed population. Chest 2004;125:2140-5
40. Programme de Médicalisation des Systèmes d'Information (PMSI). Paris, 2006. Available at: www.pmsi.fr [last accessed 30 January 2007]
41. Williams D, Hopkins S. Safety of trovafloxacin in treatment of lower respiratory tract infections. Eur J Clin Microbiol InfectDis 1998;17:454-8
42. Flanders SA, Halm EA. Guidelines for community-acquired pneumonia: are they reflected in practice? Treat Respir Med 2004;3:67-77
43. Singer ME, Harding I, Jacobs MR, Jaffe DH. Impact of antimicrobial resistance on health outcomes in the outpatient treatment of adult community-acquired pneumonia: a probability model. J Antimicrob Chemother 2003;51:1269-82
44. Sabes-Figuera R, Segu JL, Puig-Junoy J, Torres A. Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia. Eur J Health Econ 2007: published online 13 January 2007, doi: 10.1007/s10198-006-0019-0
45. Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics 2002;20:513-28